Drugs / BMS-986242
last change Aug 2018 re-read 3 minutes ago

BMS-986242

Developed for
cancer
Investigated by
Bristol-Myers Squibb

Trials 1

2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03351231 Nov 2017 → Aug 2018 cancer Bristol-Myers Squibb Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BMS-986242 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03351231 ↗